Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

New Strong Sell Stocks for January 19th


Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:

Aprea Therapeutics APRE is a biopharmaceutical company which is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Zacks Consensus Estimate for its current year earnings has been revised almost 61.5% downward over the last 60 days.

New Fortress Energy NFE is an integrated gas-to-power company which develops, finances and constructs energy infrastructure assets. The Zacks Consensus Estimate for its current year earnings has been revised almost 16.7% downward over the last 60 days.

Caesars Entertainment CZR is a diversified gaming and hospitality company based in Reno, NV. The Zacks Consensus Estimate for its current year earnings has been revised 5.3% downward over the last 60 days.

View the entire Zacks Rank #5 List.

#1 Semiconductor Stock to Buy (Not NVDA)

The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.

One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.

See This Stock Now for Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Caesars Entertainment, Inc. (CZR): Free Stock Analysis Report
 
New Fortress Energy LLC (NFE): Free Stock Analysis Report
 
Aprea Therapeutics, Inc. (APRE): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research


Source Zacks-com

Like: 0
Share
At Zacks, we are dedicated to independent investment research, helping investors succeed through tools like our Zacks Rank stock-rating system, which has averaged +23.89% annual returns since 1988. Founded on the discovery that earnings estimate revisions drive stock prices, we offer purely mathematical, unbiased ratings, along with additional innovations like the Price Response Indicator, Earnings ESP, and specialized rankings for mutual funds and ETFs.
...
Legal notice

Comments